Display options
Cite
Kim GN, Choi JA, Wu K, et al. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2. PLoS Pathog. 2021;17(12):e1010092doi: 10.1371/journal.ppat.1010092.
Kim, G. N., Choi, J. A., Wu, K., Saeedian, N., Yang, E., Park, H., Woo, S. J., Lim, G., Kim, S. G., Eo, S. K., Jeong, H. W., Kim, T., Chang, J. H., Seo, S. H., Kim, N. H., Choi, E., Choo, S., Lee, S., Winterborn, A., Li, Y., Parham, K., Donovan, J. M., Fenton, B., Dikeakos, J. D., Dekaban, G. A., Haeryfar, S. M. M., Troyer, R. M., Arts, E. J., Barr, S. D., Song, M., & Kang, C. Y. (2021). A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2. PLoS pathogens, 17(12), e1010092. https://doi.org/10.1371/journal.ppat.1010092
Kim, Gyoung Nyoun, et al. "A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2." PLoS pathogens vol. 17,12 (2021): e1010092. doi: https://doi.org/10.1371/journal.ppat.1010092
Kim GN, Choi JA, Wu K, Saeedian N, Yang E, Park H, Woo SJ, Lim G, Kim SG, Eo SK, Jeong HW, Kim T, Chang JH, Seo SH, Kim NH, Choi E, Choo S, Lee S, Winterborn A, Li Y, Parham K, Donovan JM, Fenton B, Dikeakos JD, Dekaban GA, Haeryfar SMM, Troyer RM, Arts EJ, Barr SD, Song M, Kang CY. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2. PLoS Pathog. 2021 Dec 16;17(12):e1010092. doi: 10.1371/journal.ppat.1010092. eCollection 2021 Dec. PMID: 34914812; PMCID: PMC8675757.
Copy Download .nbib Format: NLM
Share it on

PLoS Pathog. 2021 Dec 16;17(12):e1010092. doi: 10.1371/journal.ppat.1010092. eCollection 2021 Dec.

A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.

PLoS pathogens

Gyoung Nyoun Kim, Jung-Ah Choi, Kunyu Wu, Nasrin Saeedian, Eunji Yang, Hayan Park, Sun-Je Woo, Gippeum Lim, Seong-Gyu Kim, Su-Kyeong Eo, Hoe Won Jeong, Taewoo Kim, Jae-Hyung Chang, Sang Hwan Seo, Na Hyung Kim, Eunsil Choi, Seungho Choo, Sangkyun Lee, Andrew Winterborn, Yue Li, Kate Parham, Justin M Donovan, Brock Fenton, Jimmy D Dikeakos, Gregory A Dekaban, S M Mansour Haeryfar, Ryan M Troyer, Eric J Arts, Stephen D Barr, Manki Song, C Yong Kang

Affiliations

  1. Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
  2. International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
  3. Sumagen, 4F Dongwon Bldg, Teheran-ro 77-gil, Gangnam-gu, Seoul, Korea.
  4. Animal Facility, Queen's University, Kinston, Ontario, Canada.
  5. Department of Biology, Faculty of Science, The University of Western Ontario, London, Ontario, Canada.
  6. Molecular Medicine Research Laboratories, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.

PMID: 34914812 PMCID: PMC8675757 DOI: 10.1371/journal.ppat.1010092

Abstract

The development of safe and effective vaccines to prevent SARS-CoV-2 infections remains an urgent priority worldwide. We have used a recombinant vesicular stomatitis virus (rVSV)-based prime-boost immunization strategy to develop an effective COVID-19 vaccine candidate. We have constructed VSV genomes carrying exogenous genes resulting in the production of avirulent rVSV carrying the full-length spike protein (SF), the S1 subunit, or the receptor-binding domain (RBD) plus envelope (E) protein of SARS-CoV-2. Adding the honeybee melittin signal peptide (msp) to the N-terminus enhanced the protein expression, and adding the VSV G protein transmembrane domain and the cytoplasmic tail (Gtc) enhanced protein incorporation into pseudotype VSV. All rVSVs expressed three different forms of SARS-CoV-2 spike proteins, but chimeras with VSV-Gtc demonstrated the highest rVSV-associated expression. In immunized mice, rVSV with chimeric S protein-Gtc derivatives induced the highest level of potent neutralizing antibodies and T cell responses, and rVSV harboring the full-length msp-SF-Gtc proved to be the superior immunogen. More importantly, rVSV-msp-SF-Gtc vaccinated animals were completely protected from a subsequent SARS-CoV-2 challenge. Overall, we have developed an efficient strategy to induce a protective response in SARS-CoV-2 challenged immunized mice. Vaccination with our rVSV-based vector may be an effective solution in the global fight against COVID-19.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

  1. Nature. 2020 Oct;586(7830):578-582 - PubMed
  2. Lancet. 2021 Jan 9;397(10269):99-111 - PubMed
  3. Lancet. 2021 Feb 20;397(10275):671-681 - PubMed
  4. Open Forum Infect Dis. 2015 Jun 05;2(3):ofv082 - PubMed
  5. Nat Med. 2020 Jul;26(7):1017-1032 - PubMed
  6. Front Immunol. 2020 Sep 04;11:565278 - PubMed
  7. Nature. 2020 Mar;579(7798):270-273 - PubMed
  8. Int J Med Sci. 2020 Jun 18;17(11):1522-1531 - PubMed
  9. Nat Microbiol. 2017 May 22;2:17078 - PubMed
  10. J Virol. 1998 Jun;72(6):4704-11 - PubMed
  11. FEBS Lett. 2002 Dec 4;532(1-2):107-10 - PubMed
  12. Mol Cell. 2020 May 21;78(4):779-784.e5 - PubMed
  13. Hum Vaccin Immunother. 2018;14(9):2107-2113 - PubMed
  14. J Virol. 2011 Dec;85(23):12781-91 - PubMed
  15. Virology. 1994 Oct;204(1):266-78 - PubMed
  16. Am J Respir Crit Care Med. 2020 Sep 1;202(5):756-759 - PubMed
  17. Cell. 2020 Jun 25;181(7):1489-1501.e15 - PubMed
  18. Nature. 2020 Aug;584(7821):450-456 - PubMed
  19. J Virol. 2004 May;78(10):5458-65 - PubMed
  20. J Virol. 2015 Jun;89(12):6338-51 - PubMed
  21. J Gen Virol. 1972 Sep;16(3):391-8 - PubMed
  22. J Virol. 1999 Jan;73(1):251-9 - PubMed
  23. J Virol. 2008 Jan;82(1):207-19 - PubMed
  24. Viruses. 2019 Mar 19;11(3): - PubMed
  25. Cell. 2020 May 28;181(5):1016-1035.e19 - PubMed
  26. N Engl J Med. 2021 Feb 4;384(5):403-416 - PubMed
  27. Lancet Infect Dis. 2020 May;20(5):533-534 - PubMed
  28. J Gen Virol. 2021 Apr;102(4): - PubMed
  29. Cell Host Microbe. 2020 Sep 9;28(3):465-474.e4 - PubMed
  30. Glycobiology. 2017 Jul 1;27(7):619-624 - PubMed
  31. J Virol. 2011 May;85(9):4602-5 - PubMed
  32. Science. 2020 Dec 4;370(6521):1227-1230 - PubMed
  33. Nat Commun. 2020 Oct 15;11(1):5214 - PubMed
  34. Virology. 2007 Jan 5;357(1):41-53 - PubMed
  35. PLoS Med. 2005 Jun;2(6):e183 - PubMed
  36. Prog Mol Biol Transl Sci. 2015;129:285-326 - PubMed
  37. Curr Opin Virol. 2018 Dec;33:1-6 - PubMed
  38. J Virol. 2008 Sep;82(18):9273-7 - PubMed
  39. NPJ Vaccines. 2020 Jan 10;5(1):4 - PubMed
  40. Nat Genet. 2020 Dec;52(12):1283-1293 - PubMed
  41. Sci Adv. 2020 Dec 4;6(49): - PubMed
  42. Trends Microbiol. 2007 May;15(5):211-8 - PubMed
  43. J Virol. 2007 Feb;81(4):2056-64 - PubMed
  44. Lancet Infect Dis. 2015 Oct;15(10):1156-1166 - PubMed
  45. Lancet. 2020 Feb 15;395(10223):507-513 - PubMed
  46. Vaccine. 2016 Dec 12;34(51):6597-6609 - PubMed
  47. Cell. 2020 Apr 16;181(2):271-280.e8 - PubMed
  48. Cell Rep Med. 2021 Feb 16;2(2):100204 - PubMed
  49. J Virol. 2010 Apr;84(7):3552-61 - PubMed
  50. PLoS Pathog. 2021 Jan 19;17(1):e1009195 - PubMed
  51. Cell. 2001 Sep 7;106(5):539-49 - PubMed
  52. N Engl J Med. 2020 Dec 31;383(27):2603-2615 - PubMed
  53. J Virol. 2000 Sep;74(17):7895-902 - PubMed
  54. Nat Med. 2005 Jul;11(7):786-90 - PubMed
  55. AIDS Res Hum Retroviruses. 2004 Sep;20(9):989-1004 - PubMed
  56. Nat Commun. 2020 Dec 16;11(1):6402 - PubMed
  57. Life Sci Alliance. 2020 Jul 23;3(9): - PubMed

Publication Types